首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1672193

全球 PARP 抑制劑生物標記市場研究報告 - 產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年

Global PARP Inhibitor Biomarkers Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年03月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 PARP 抑制劑生物標記市場規模預計將從 2024 年的 10.1 億美元成長到 2033 年的 22.3 億美元，在 2026 年至 2033 年的預測期內呈現 9.11% 的強勁年複合成長率(CAGR)。

受癌症發病率上升和標靶治療需求上升的推動，PARP 抑制劑生物標記市場正在經歷顯著成長。 PARP 抑制劑是一類在治療具有特定基因突變的癌症（特別是乳癌和卵巢癌）方面顯示出良好前景的藥物。隨著對癌症生物學理解的不斷進步，識別和驗證可預測 PARP 抑制劑反應的生物標記對於個人化醫療變得至關重要。隨著研究人員和臨床醫生尋求最佳化治療策略和改善患者治療效果，預計市場將會擴大。

此外，生物標記發現技術的進步正在推動 PARP 抑制劑生物標記市場的創新。下一代定序、液體活體組織切片技術和生物資訊學工具的發展正在增強識別和驗證與 PARP 抑制劑功效相關的生物標記的能力。這些創新不僅提高了生物標記檢測的準確性，而且還促進了可指導治療決策的伴隨診斷的發展。隨著研究不斷探索新的生物標記及其臨床應用，在癌症治療精準度提高的推動下，市場可能會進一步擴大。

此外，對個人化醫療和以患者為中心的方法的日益重視正在塑造 PARP 抑制劑生物標記模式。隨著醫療保健提供者越來越重視考慮個別患者特徵的客製化治療計劃，對可以為治療決策提供參考的可靠生物標記的需求可能會增加。這一趨勢在臨床試驗和藥物開發中尤其重要，其中生物標記驅動的策略可以提高新療法的效率和成功率。隨著 PARP 抑制劑生物標記市場不斷發展，技術進步、個人化醫療的重點以及對有效癌症治療的需求將在塑造其未來發展方面發揮關鍵作用。

我們的報告經過精心製作，為客戶提供有關各個行業和市場的全面且可操作的見解。每份報告都包含幾個關鍵部分，以確保徹底了解市場格局：

市場概覽：市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本節探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準將市場細分為不同的細分市場。該分析強調了每個部分的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本節深入介紹領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，預測特定時期內的市場規模和成長趨勢。這包括定量分析和圖形表示來說明未來的市場軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前和新興的市場趨勢、技術創新和潛在投資領域。本節提供未來市場發展和成長前景的見解。

區域展望
介紹
北美銷售分析
- 概述、歷史和預測數據銷售分析
- 北美各細分市場銷售分析
- 北美各國銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測數據銷售分析
- 歐洲各細分市場銷售分析
- 歐洲各國銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測數據銷售分析
- 亞太地區分部銷售分析
- 亞太地區國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測數據銷售分析
- 拉丁美洲各細分市場銷售分析
- 拉丁美洲各國銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測數據銷售分析
- 中東和非洲分部銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第 9 章：PARP 抑制劑生物標記公司的競爭格局

PARP 抑制劑生物標記市場競爭
夥伴關係/合作/協議
合併與收購
新產品發布
其他進展

第10章：公司簡介

頂級公司市佔率分析
市場集中度
Myriad Genetics Inc.

公司概況
公司收入
產品
最新動態

Ambry Genetics

公司概況
公司收入
產品
最新動態

Thermo Fisher Scientific Inc.

公司概況
公司收入
產品
最新動態

Illumina Inc.

公司概況
公司收入
產品
最新動態

Centogene NV

公司概況
公司收入
產品
最新動態

Amoy Diagnostics Co. Ltd.

公司概況
公司收入
產品
最新動態

Invitae Corporation

公司概況
公司收入
產品
最新動態

NeoGenomics Laboratories

公司概況
公司收入
產品
最新動態

QIAGEN

公司概況
公司收入
產品
最新動態

Agilent Technologies Inc

公司概況
公司收入
產品
最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，對於私人公司，可能不予涵蓋

簡介目錄圖表

Product Code: VMR112114327

Global PARP Inhibitor Biomarkers Market size is anticipated to grow from USD 1.01 Billion in 2024 to USD 2.23 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 9.11% during the forecast period of 2026 to 2033.

The PARP inhibitor biomarkers market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. PARP inhibitors are a class of drugs that have shown promise in treating cancers with specific genetic mutations, particularly in breast and ovarian cancers. As the understanding of cancer biology advances, the identification and validation of biomarkers that predict response to PARP inhibitors are becoming critical for personalized medicine. This market is expected to expand as researchers and clinicians seek to optimize treatment strategies and improve patient outcomes.

Moreover, advancements in biomarker discovery technologies are propelling innovation within the PARP inhibitor biomarkers market. The development of next-generation sequencing, liquid biopsy techniques, and bioinformatics tools is enhancing the ability to identify and validate biomarkers associated with PARP inhibitor efficacy. These innovations not only improve the accuracy of biomarker testing but also facilitate the development of companion diagnostics that can guide treatment decisions. As research continues to explore new biomarkers and their clinical applications, the market is likely to expand further, driven by the promise of improved precision in cancer therapy.

Additionally, the growing emphasis on personalized medicine and patient-centric approaches is shaping the PARP inhibitor biomarkers landscape. As healthcare providers increasingly prioritize tailored treatment plans that consider individual patient characteristics, the demand for reliable biomarkers that can inform treatment decisions is likely to increase. This trend is particularly relevant in the context of clinical trials and drug development, where biomarker-driven strategies can enhance the efficiency and success rates of new therapies. As the PARP inhibitor biomarkers market continues to evolve, the combination of technological advancements, a focus on personalized medicine, and the need for effective cancer treatments will play a crucial role in shaping its future trajectory.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Product

Kits
Assays

By Services

BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others

By Application

Breast Cancer
Ovarian Cancer
Others
COMPANIES PROFILED
Myriad Genetics Inc.
Ambry Genetics
Thermo Fisher Scientific Inc.
Illumina Inc.
Centogene N.V.
Amoy Diagnostics Co. Ltd.
Invitae Corporation
NeoGenomics Laboratories
QIAGEN
Agilent Technologies Inc.
The above list can be customized.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PARP INHIBITOR BIOMARKERS INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porters Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Services
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data Analysis By Product
5.3. Kits Historic and Forecast Sales By Regions
5.4. Assays Historic and Forecast Sales By Regions

6. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY SERVICES

6.1. Overview By Services
6.2. Historical and Forecast Data Analysis By Services
6.3. BRCA 1 & 2 Testing Historic and Forecast Sales By Regions
6.4. HRD Testing Historic and Forecast Sales By Regions
6.5. HRR Testing Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data Analysis By Application
7.3. Breast Cancer Historic and Forecast Sales By Regions
7.4. Ovarian Cancer Historic and Forecast Sales By Regions
7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL PARP INHIBITOR BIOMARKERS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PARP INHIBITOR BIOMARKERS COMPANIES

9.1. PARP Inhibitor Biomarkers Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PARP INHIBITOR BIOMARKERS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Myriad Genetics Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Ambry Genetics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Illumina Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Centogene N.V.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amoy Diagnostics Co. Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Invitae Corporation
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. NeoGenomics Laboratories
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. QIAGEN
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Agilent Technologies Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Product (USD MN)
Kits Market Sales By Geography (USD MN)
Assays Market Sales By Geography (USD MN)
Analysis By Services (USD MN)
BRCA 1 & 2 Testing Market Sales By Geography (USD MN)
HRD Testing Market Sales By Geography (USD MN)
HRR Testing Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By Application (USD MN)
Breast Cancer Market Sales By Geography (USD MN)
Ovarian Cancer Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global PARP Inhibitor Biomarkers Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of PARP Inhibitor Biomarkers Report
Market Research Process
Market Research Methodology
Global PARP Inhibitor Biomarkers Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Product
Market Attractiveness Analysis By Services
Market Attractiveness Analysis By Application
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Product (USD MN)
Kits Market Sales By Geography (USD MN)
Assays Market Sales By Geography (USD MN)
Global Market Analysis By Services (USD MN)
BRCA 1 & 2 Testing Market Sales By Geography (USD MN)
HRD Testing Market Sales By Geography (USD MN)
HRR Testing Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By Application (USD MN)
Breast Cancer Market Sales By Geography (USD MN)
Ovarian Cancer Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.